Mergers and Acquistions news from FierceBiotech
News
Parexel, Quintiles may battle for ClinPhone
CRO Parexel has made a $182 million bid for U.K.-based ClinPhone, but it may be facing competition from Quintiles, the world's largest private CRO. ClinPhone helps drug developers select trial Read more...
Report: Pfizer makes counter-offer for Ranbaxy
Pfizer may be crashing Daiichi Sankyo's party. Business Standard is reporting that Pfizer is considering a counter-offer for Ranbaxy, India's largest drugmaker. The rumor comes on the heels of the Read more...
Invitrogen, Applera agree on $6.7B merger
Two big suppliers to the drug development business are merging. Invitrogen has agreed to acquire all of the shares of Applera's Read more...
Daiichi Sankyo acquires Ranbaxy in $4.6B deal
Ranbaxy's drive to become a research-based drug developer and major manufacturer has led it straight into the Read more...
CytRx inks deal to buy Innovive in $21M acquisition
CytRx has inked a deal to buy Innovive Pharmaceuticals, adding its four experimental oncology therapies to its pipeline. The combined company will own a 49% interest in RXi Pharmaceuticals. The deal Read more...
Emergent BioSolutions buys flu vaccine maker
Emergent BioSolutions has inked a deal to acquire the Protein Sciences Corporation assets for up to $75 million. The move is part of Emergent's strategy to expand its product portfolio with a drug Read more...
FDA staffers say that Eisai sedative appears safe
FDA staffers say that an experimental sedative developed by Eisai appears to be safe, but wants outside experts to consider whether it's safe enough to be administered by workers untrained in Read more...
DSM to acquire Polymer Technology Group
Amsterdam-based Royal DSM has inked a deal to buy the Polymer Technology Group in Berkeley, CA, making it a world leader in polymers for biomedical research. The financial details were not Read more...
Abraxis buys Shimoda, subsidiary
Abraxis BioScience has completed acquisition of South Africa's Shimoda Biotech and its subsidiary, Platco Technologies. Abraxis bought the companies for $15 million up-front, plus potential Read more...
Teva plans aggressive move into biogenerics
Anyone looking for some real insight into Teva's growth strategy should spend some time with a new Globes article that digs in deep. Shlomo Yanai, who stepped in as CEO a year ago, plans to double Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends